None listed
Conditions
Brief summary
Topical atropine is a cycloplegic (reduces or temporarily eliminates focusing ability) and mydriatic (increases pupil size) agent that has shown promising results in slowing myopia (nearsightedness) progression in children in a dose-dependent manner. However, the exact mechanism of topical atropine slowing myopia is still unclear. Atropine is known to reduce the focusing ability and increase the pupil size of the eye; however, the effect of atropine on the ability of the eye to detect the stimulus properties such as contrast, colour, and motion remains unknown, and it is possible that atropine impact these functions, which may contribute to its effect in slowing myopia progression. The primary objective of this study is to examine the impact of 0.05 % atropine sulfate eye drops for approximately 2 hours on a range of basic visual functions (contrast sensitivity, colour, and motion detection), pupil size, and image quality. This research is expected to provide a greater understanding of the effect of 0.05 % atropine on the blur detection mechanism of the eye and associated visual function changes and the potential mechanisms underlying myopia development and progression. To achieve this, 0.05 % atropine will be applied to the participant's eye, and the outcome measurements will be taken.
Interventions
Participants will receive 0.05% atropine sulfate eye drops, taken just once, as one drop in one eye. The study measurements will be taken after 30 minutes of eye drop instillation. This visit will take approximately 1 hour.
The study's investigators will only install the eye drop during the study visit, so no adherence measurements are required.
All procedures including drop instillation will be conducted at the School of Optometry and Vision Science, UNSW, and be administered by a Ph.D. can
Participants will receive 0.05% atropine sulfate eye drops, taken just once, as one drop in one eye. The study measurements will be taken after 30 minutes of eye drop instillation. This visit will take approximately 1 hour. The study's investigators will only install the eye drop during the study visit, so no adherence measurements are required. All procedures including drop instillation will be conducted at the School of Optometry and Vision Science, UNSW, and be administered by a Ph.D. candidate under the supervision of Australian registered optometrists.”
Sponsors
Unversity of New South Wales -UNSW
Study design
Allocation
Non-randomised trial
Intervention model
Single group
Primary purpose
Treatment
Masking
Open (masking not used)
Eligibility
Sex/Gender
All
Age
18 Years to 35 Years
Healthy volunteers
No
Inclusion criteria
•Aged between 18-35 years . •Have normal general and eye health. •Have an optical prescription between -0.50 and -4.00D; with less than -1.50D of astigmatism. •Have ‘normal’ vision, measuring 6/7.5 or better with correction (0,2 LogMar). •Have a normal color vision. •Have normal intraocular pressure (IOP). •Willing to attend two study visits.
Exclusion criteria
•Have used an atropine eye drop within 2 weeks prior to study enrolment. •Have any eye diseases including inflammation, infection, or allergy. •Have a history of allergic reactions to eye medications. •Are at risk of glaucoma. •Are currently using any eye medications or antidepression. •Women who are pregnant, planning to become pregnant, or breastfeeding.
Outcome results
None listed